Skip to main content
twitter
facebook
linkedin
News & Media
Subscribe
Contact
Hit enter to search or ESC to close
Close Search
Menu
About Us
Company Overview
Team
Collaborations
Careers
Our Science
Psychedelic Therapies
CBD Combination Therapies
Development Programs
Investors
Investor Overview
Press Releases
Events + Presentations
Company Information
SEC Filings
Stock Information
Corporate Governance
News Alerts
Investors
Press Releases
Overview
Press Releases
Events + Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
News Alerts
Recent Press Releases
Enveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to Shareholders
May 11, 2022
Enveric Biosciences to Host Fireside Chat with Dr. Bob Dagher, Chief Medical Officer, on May 17th at 10:00 a.m. ET
May 5, 2022
Enveric Biosciences Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
May 3, 2022
Enveric Biosciences to Participate in Upcoming Investor Conferences in April 2022
April 6, 2022
Enveric Biosciences Reports Full-Year 2021 Financial Results and Provides Business Update
March 31, 2022
Enveric Biosciences Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application
March 29, 2022
View All Press Releases
Close Menu
About Us
Company Overview
Team
Collaborations
Careers
Our Science
Psychedelic Therapies
CBD Combination Therapies
Development Programs
Investors
Investor Overview
Press Releases
Events + Presentations
Company Information
SEC Filings
Stock Information
Corporate Governance
News Alerts
News & Media
Subscribe
Contact